DNA manufacturing
Redefined
We are redefining next generation genetic medicine with synthetic DNA amplification technology
Eliminate the limitations of plasmid with synthetic DNA
Our synthetic, cell-free DNA amplification technology eases manufacturing burdens, reduces costs, and eliminates risk, supporting each development stage, from preclinical to commercialization.
Robust scalability
4x faster
Enhanced safety
Purity
compared to pDNA
From discovery to clinic
Efficient by design
No bacterial sequences
High-Quality Synthetic DNA for Your Next-Gen Medicine Needs
With state-of-the-art, application-specific synthetic DNA solutions, 4basebio is a leading DNA company supporting the diverse needs of next-generation therapies. With synthetic DNA, you’ll reach proof-of-concept and subsequent clinical milestones faster and more efficiently while ensuring the highest safety and quality standards for your genetic medicines.
mRNA vaccines & therapeutics
Improve your mRNA yields and simplify production workflows.
Viral vectors
Mitigate packing of exogenous sequences, while achieving equivalent viral titers using less DNA input material.
Gene editing
Increase gene editing efficiency with ssDNA templates across a wide range of gene editing applications.
Custom manufacturing that moves at the speed of innovation
4basebio delivers high-quality synthetic DNA through proprietary cell-free amplification technology, eliminating the bottlenecks of traditional plasmid DNA production. We remove long lead times, host-cell contaminants, and antibiotic resistance genes, giving you a faster, cleaner path from research to clinic.
Our team combines deep molecular biology expertise with GMP-grade manufacturing capabilities. Whether you need research-grade material or full-scale clinical production, we provide the quality, consistency, and regulatory rigor to accelerate your next-generation therapy.
Latest news from 4basebio
07 JUL 2025 / PRESS RELEASE
Influenza Research Consortium announces £1.2 million (C$2.2 million) in funding for the development of a novel broad-spectrum vaccine
4basebio PLC, ConserV Bioscience Limited, Pegasus Biotech, the University of Leicester, and the National Research Council of Canada (NRC) announce that the UK and Canadian governments are providing up to a combined £1.2 million (C$2.2 million) in funding to develop and manufacture a broadly protective influenza vaccine. This project is supported through the Canada-UK 2024-25 collaborative industrial R&D call for proposals on enabling technologies and innovations for biomanufacturing of biologics and advanced therapeutics.
4basebio PLC (AIM: 4BB), an innovation-led provider of novel synthetic DNA products announces that, following Investigational New Drug (IND) approval from the FDA, a global Tier 1 pharmaceutical partner has begun dosing patients with an mRNA product developed using 4basebio’s proprietary opDNA® template. The Company signed the supply agreement with the partner in April 2024. Specific details of the clinical trial are not able to be disclosed at this time due to innovator confidentiality.
4basebio synthetic opDNA® utilised in PhaseI/II US clinical
27 OCT 2025 / PRESS RELEASE
07 AUG 2025 / PRESS RELEASE
We are excited to announce that a Tier 1 pharmaceutical partner has received FDA approval for their Investigational New Drug (IND) application for an mRNA vaccine developed using 4basebio’s proprietary opDNA® template.
4basebio synthetic DNA powers tier 1 pharma IND filing for mRNA vaccine
Technology
Find out more about our enzymatic manufacturing process and the benefits of synthetic DNA
Synthetic DNA
Discover our RUO, HQ and GMP-grade synthetic DNA, designed for every stage from discovery to commercial production.